These large numbers shall clearly require massive inputs in terms of infrastructural facilities, technological upgradation of health-care facilities, trained manpower, technical expertise and costs. The financial implication of the CHD epidemic in developing countries is only now being realized. 2 CHD is a chronic disease and medication involves a lifelong commitment. Primary as well as secondary prevention offers the most painless and cost-effective strategy for control of the cardiovascular disease epidemic. 3 Recent studies have shown that lifestyle changes (smoking/tobacco cessation, increased physical activity, stress management, weight control) and poly-pharmacy (aspirin, statin, ACE inhibitor, beta-blocker and certain vitamins) can primarily prevent more than 75% of heart attacks. 4 Secondary prevention studies report that these therapies reduce the major cardiovascular event rates from 8-10% per year to less than 2% per year in patients with established stable coronary artery disease. 3, 5 Multiple large observational and interventional studies in Europe and North America have consistently shown the effectiveness of such strategies.
In India, as is true worldwide, cost of treatment is a major concern. India is one of the few countries of the world where most of the medicine costs are borne directly by the patient. According to the World Health Organization World Health Report (2004) only 17% costs of medical treatment are borne by third-party payers or the government in India. Given this scenario it is very difficult to calculate direct as well as indirect costs of treatment of various diseases at a macrolevel. To determine the direct costs of preventive treatment in patients with CHD per patient (microlevel) we analysed the available cost-data. There are eight groups of drugs that are commonly used, either singly or in combinations, for long-term treatment of patients with CHD. These groups are antihypertensive medications (ACE inhibitors/angiotensin receptor blockers beta blockers, diuretics, calcium channel blockers), lipid lowering drugs (statins), antiplatelet drugs (aspirin, clopidogrel), and insulin sensitizers (metformin, pioglitazone ( Table 1) .
Price of various compounds in each of these groups were taken from Indian Drug Review, 6 a bimonthly journal that provides retail costs of almost all the drugs available in this country. Various commonly used molecules in each group, number of manufacturers/suppliers of the drug, and median daily price provided by various Indian generic and semigeneric companies, and annual costs in rupees are reported in Table 1 . There is a large variation in number of companies manufacturing a particular molecule (depending upon margin of profits!!) as well as price. Large standard deviations are observed in price of newer molecules such as ramipril, clopidogrel, atorvastatin, and rosuvastatin. The median annual costs also vary considerably as shown in Table 1 .
Recent clinical evidence suggests that all patients with stable CHD as well as high-risk groups should be on a combination pharmacotherapy that includes a beta-blocker, statin, aspirin, and ACE inhibitor along with lifestyle therapies. 3 The polypill approach suggested by Wald and Law uses the following molecules: enalapril, atorvastatin, hydrochlorothiazide, atenolol, aspirin, and folic acid. 4 Recent evidence from multiple clinical trials suggests that ACE inhibitor of choice could be ramipril or perindopril, 5 and folic acid is of doubtful benefit in such patients. 7 Therefore, a rational combination would be the use of ramipril or perindopril, atenolol, atorvastatin, and aspirin in all the patients of CHD. Different permutations and combinations of all the above groups of drugs may be more suited in specific subgroups and Tauzeeh has provided a list of possible combinations of the classical Polypill. 4, 8 For South Asians it is suggested that pioglitazone should be substituted for hydrochlorothiazide given the high prevalence of impaired glucose tolerance (Polypill-A), for Blacks a dihydropyridine calcium channel blockers for ACE inhibitor (Polypill-B), clopidogrel for persons allergic to aspirin (Polypill-C), and for diabetics there is a need to add metformin or a sulfonylurea (Polypill-D). Median annual retail cost of the standard polypill in India would be Indian Rupees (INR) 4383 (d57), while for Polypill-A would be INR 4164 (d54), Polypill-B would be INR 4415 (d58), Polypill-C would be INR 6536 (d85), and for Polypill D it would be INR 4419 (d57). Many patients with CHD also have significant comorbidities such as hypertension, diabetes, hypercholesterolemia, or renal disease. Additional costs to treat these conditions can be substantial (Table 2) . Therefore, the annual median cost for evidencebased therapy 3 for subjects with established CHD in India would be INR 5329 (d69). This includes costs of ramipril 5 mg, atorvastatin 10 mg, aspirin 150 mg and atenolol 25 mg per day. These costs are very low if they are evaluated in context of a developed country such as Britain (Table 1) . However, considering that there are more than 30 million CHD patients in India the annual cost would be massive. However, in India, as in most of the developing countries of the world there is a very low awareness of CHD and population-based studies in India have shown that only a quarter of the patient population is aware of the condition and of these less than 10% are on proper therapies and controlled. 1, 2, 9 This would translate into 7.5 million CHD patients who could be on some form of treatment. At the minimum these costs would be INR 40 billion (d520 million) annually and if all the patients were on treatment the corresponding cost would be INR 160 billion (d2.1 billion). Therefore, at current retail prices the CHD polypharmacy would cost the economy Indian Rupees 40-160 billions (d 0.5-2.1 billion). However, drug costs are not the only issue in economic evaluation and other direct expenses such as hospital costs, consultant's fee, and investigations would double the direct costs each year (d4.2 billion) as it has been reported that medicine costs contribute to about 50% of the direct medical costs in India. 10 The gross national product of India at current prices is about INR 25 000 billion (d325 billion) 11 and the underestimated medicinal costs for CHD could vary from 0.2 to 1.3% of the gross national product. A very large amount by any standards. 
